- Medicine - Nov 21 MVLS academics named as Highly Cited Researchers
- Medicine - Nov 21 Four Queen Mary University of London scientists make Highly Cited Researchers 2014 List
- Life Sciences - Nov 21 Report highlights opportunities and risks associated with synthetic biology and bioengineering
- Administration - Nov 21 Worldwide campaign on abortion raises $300m, UCL Lancet lecture told
- Medicine - Nov 20 Systems of change behind everything from climate to health
- Medicine - Nov 20 Young people have more varied sex lives than their parents
- Medicine - Nov 17 Foodbank users report benefit delays, adverse life events
- Physics - Nov 17 Controlling growth of organic crystals with high- powered magnets could have major benefits for pharmaceutical development
- Medicine - Nov 17 UofG signs historic agreement with Thailand’s Mahidol University
- Life Sciences - Nov 17 Puppy poo needed to monitor antibiotic- resistant bacteria
- Medicine - Nov 16 From Hong Kong high- rise to world- leading renal researcher
- Medicine - Nov 16 New talking therapy could help cancer survivors cope after treatment
FDA approval for University spin-out
A Cardiff University life sciences spin-out company has set its sights on the lucrative US medical device market after successfully securing FDA (Food and Drug Administration) approval for its Ultravision device.
Alesi Surgical, based at the Cardiff Medicentre, becomes a member of a select group of only 26 medical device companies worldwide in the last 12 months that have successfully navigated the FDA De Novo regulatory review process.
“We are thrilled to have gained FDA approval for our Ultravision device that will now allow us to target the US market,” said Dr Dominic Griffiths, Managing Director of Alesi Surgical.
A world first
Invented by Neil Warren a founder of WIMAT in Cardiff, the Ultravision device is a world first that clears the vapour and particulate matter generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery through the use of electrostatic technology. The technology dramatically and effortlessly improves visibility for surgeons that is otherwise rapidly obscured by this “plume” or “surgical smoke”.
“Absolutely awful view whilst it was turned off. Miraculous difference when it was switched on,” said Mr Andrew Miles, Consultant Colorectal Surgeon, Royal Hampshire County Hospital, Winchester.
The innovative device, which produces a small, low-energy electrostatic charge similar to the principal of static electricity, is able to greatly improve visibility for surgeons by actively getting rid of surgical ‘smoke’.
The technology also benefits the patient as it minimises the amount of cold, dry carbon dioxide gas – used to create a working space inside the abdomen – which a patient is exposed to during the keyhole procedure.
It is not uncommon for abdominal keyhole procedures to require several hundred litres of this gas to clear the visual field throughout the procedure. Excessive use of carbon dioxide contributes to post-surgical pain and prolongs recovery time for the patient.
Despite concerns over the potential consequences of long-term exposure, the smoke produced during surgery is often released into the operating room where it can be breathed in by hospital operating room staff. However, the use of Ultravision prevents the release of the smoke into the operating room during surgery, helping to address this health and safety hazard for healthcare staff.
Dr Griffith said: “Ultravision helps optimize the efficiency of laparoscopic surgery whilst at the same time providing additional benefits to patients and staff.
"Gaining FDA approval for Ultravision allows us to continue the progress and development in the US market..."
"The combination of these two major achievements places us in a strong position to enter 2017 with confidence.”
Alesi Surgical launched in 2009 as a spin out from the internationally recognised Welsh Institute of Minimally Invasive Surgery, part of Cardiff University. To date, Alesi has secured £6.1m worth of venture capital funding, principally from its lead investors IP Group PLC and Finance Wales Limited.
Last job offers
- Life Sciences - 20.11
Assistant and Associate Professor Opportunities in Sports and Exercise Science
- Life Sciences - 17.11
Associate Professor of Neuroscience
- Life Sciences - 17.11
Associate Professor of Cardiovascular Physiology
- Medicine/Pharmacology - 17.11
Nuffield Professorship of Clinical Medicine
- Literature/Linguistics - 17.11
Official (Tutorial) Fellowship in French and Associate Professorship or Professorship of French
- Administration/Government - 17.11
Professorial Post in Public Policy (Security)
- History/Archeology - 17.11
Associate Professorship in Roman Archaeology and Art
- Medicine/Pharmacology - 14.11
Chair in Healthcare Management